Novavax, Inc. (NASDAQ:NVAX) Receives $18.00 Average Price Target from Analysts

Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have been given a consensus recommendation of "Hold" by the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $18.00.

NVAX has been the topic of a number of analyst reports. TD Cowen upgraded Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research started coverage on Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $19.00 target price on shares of Novavax in a research note on Tuesday, December 10th.

Novavax Price Performance

NVAX stock traded up $0.30 during trading on Thursday, hitting $6.54. 7,801,856 shares of the company traded hands, compared to its average volume of 8,101,517. Novavax has a 1 year low of $3.81 and a 1 year high of $23.86. The stock's 50-day simple moving average is $7.79 and its 200 day simple moving average is $9.04. The company has a market cap of $1.05 billion, a PE ratio of -2.89, a P/E/G ratio of 2.85 and a beta of 3.15.

Remove Ads

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the prior year, the firm earned ($1.44) earnings per share. Research analysts expect that Novavax will post -1.46 earnings per share for the current year.

Institutional Trading of Novavax

A number of institutional investors have recently made changes to their positions in NVAX. GF Fund Management CO. LTD. purchased a new position in Novavax during the fourth quarter worth approximately $27,000. Spire Wealth Management acquired a new position in Novavax during the fourth quarter worth $29,000. New Age Alpha Advisors LLC acquired a new position in Novavax during the 4th quarter worth about $35,000. KBC Group NV boosted its stake in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares during the period. Finally, GAMMA Investing LLC boosted its position in Novavax by 2,272.5% in the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 11,340 shares during the period. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.